Denali Therapeutics Inc. (DNLI) Operating income 2016–2025
Denali Therapeutics Inc. (DNLI) annual operating income history from SEC filings — each fiscal year as reported.
-$555.3MFY2025 · since FY2016: -$87.4M → -$555.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$555.3M | -14.0% |
| FY2024 | -$487.3M | -147.8% |
| FY2023 | -$196.7M | +42.3% |
| FY2022 | -$340.7M | -15.2% |
| FY2021 | -$295.8M | -571.6% |
| FY2020 | $62.7M | +129.4% |
| FY2019 | -$213.2M | -359.7% |
| FY2018 | -$46.4M | +48.6% |
| FY2017 | -$90.1M | -3.1% |
| FY2016 | -$87.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice